Literature DB >> 26450123

The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.

Matthew Goodyer1, Stephen E Langabeer2, Karl Haslam3, Karen Murphy1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26450123     DOI： 10.1007/s12253-015-9994-8

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


× No keyword cloud information.
  9 in total

1.  JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.

Authors:  A Pardanani; T L Lasho; S Schwager; C Finke; K Hussein; R K Pruthi; A Tefferi
Journal:  Leukemia       Date:  2007-04-26       Impact factor: 11.528

Review 2.  Molecular diagnostics of myeloproliferative neoplasms.

Authors:  Stephen E Langabeer; Hajnalka Andrikovics; Julia Asp; Beatriz Bellosillo; Serge Carillo; Karl Haslam; Lasse Kjaer; Eric Lippert; Olivier Mansier; Elisabeth Oppliger Leibundgut; Melanie J Percy; Naomi Porret; Lars Palmqvist; Jiri Schwarz; Mary F McMullin; Susanne Schnittger; Niels Pallisgaard; Sylvie Hermouet
Journal:  Eur J Haematol       Date:  2015-05-18       Impact factor: 2.997

3.  Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms.

Authors:  Karl Haslam; Karen M Molloy; Eibhlin Conneally; Stephen E Langabeer
Journal:  Clin Chem Lab Med       Date:  2014-03       Impact factor: 3.694

4.  Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.

Authors:  Eric Lippert; Olivier Mansier; Marina Migeon; Barbara Denys; Asa Nilsson; Carolina Rosmond; Laurence Lodé; Valérie Ugo; Axelle Lascaux; Beatriz Bellosillo; Joaquin Martinez-Lopez; Dina Naguib; Nathalie Gachard; Nicolas Maroc; Sylvie Hermouet
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

5.  JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.

Authors:  Camilla Nielsen; Stig E Bojesen; Børge G Nordestgaard; Klaus F Kofoed; Henrik S Birgens
Journal:  Haematologica       Date:  2014-06-06       Impact factor: 9.941

Review 6.  Splanchnic vein thrombosis in myeloproliferative neoplasms.

Authors:  Mallika Sekhar; Kathryn McVinnie; Andrew K Burroughs
Journal:  Br J Haematol       Date:  2013-07-15       Impact factor: 6.998

7.  JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.

Authors:  Francesco Dentali; Alessandro Squizzato; Lorenza Brivio; Lorena Appio; Leonardo Campiotti; Mark Crowther; Anna Maria Grandi; Walter Ageno
Journal:  Blood       Date:  2009-03-09       Impact factor: 22.113

8.  Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.

Authors:  Donatella Colaizzo; Lucio Amitrano; Maria Anna Guardascione; Giovanni Luca Tiscia; Giovanna D'Andrea; Vittoria A C Longo; Elvira Grandone; Maurizio Margaglione
Journal:  Thromb Res       Date:  2013-08-01       Impact factor: 3.944

9.  Low burden of a JAK2-V617F mutated clone in monoclonal haematopoiesis in a Japanese woman with Budd-Chiari syndrome.

Authors:  Kohtaro Toyama; Masamitsu Karasawa; Arito Yamane; Hiromi Koiso; Akihiko Yokohama; Hideki Uchiumi; Takayuki Saitoh; Hiroshi Handa; Ken Sato; Hitoshi Takagi; Shuichi Miyawaki; Hirokazu Murakami; Yoshihisa Nojima; Norifumi Tsukamoto
Journal:  Int J Hematol       Date:  2009-03-24       Impact factor: 2.490
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.